

RESEARCH ARTICLE

# Polyanionic Carboxyethyl Peptide Nucleic Acids (*ce*-PNAs): Synthesis and DNA Binding

Yuliya Kirillova<sup>1,2\*</sup>, Nataliya Boyarskaya<sup>1†</sup>, Andrey Dezhnevov<sup>1</sup>, Mariya Tankevich<sup>1,2</sup>, Ivan Prokhorov<sup>1</sup>, Anna Varizhuk<sup>2,3</sup>, Sergei Eremin<sup>1</sup>, Dmitry Esipov<sup>4</sup>, Igor Smirnov<sup>2</sup>, Galina Pozmogova<sup>2</sup>

**1** Department of Biotechnology and Bionanotechnology, Moscow State University of Fine Chemical Technologies, Moscow, Russia, **2** Department of Molecular Biology and Genetics, SRI of Physical-Chemical Medicine, Moscow, Russia, **3** Department of Structure-Functional Analysis of Biopolymers, Engelhardt Institute of Molecular Biology, Moscow, Russia, **4** Department of Bioorganic Chemistry, Biology Faculty, Moscow State University, Moscow, Russia

✉ Current Address: Biotech-Industry, Moscow, Russia.

\* [pna-mitht@yandex.ru](mailto:pna-mitht@yandex.ru)



**OPEN ACCESS**

**Citation:** Kirillova Y, Boyarskaya N, Dezhnevov A, Tankevich M, Prokhorov I, Varizhuk A, et al. (2015) Polyanionic Carboxyethyl Peptide Nucleic Acids (*ce*-PNAs): Synthesis and DNA Binding. PLoS ONE 10 (10): e0140468. doi:10.1371/journal.pone.0140468

**Editor:** Maxim Antopolsky, University of Helsinki, FINLAND

**Received:** May 6, 2015

**Accepted:** September 25, 2015

**Published:** October 15, 2015

**Copyright:** © 2015 Kirillova et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was supported by Russian Science Foundation [14-25-00013, GP] URL: (<http://www.rscf.ru>) and Russian Foundation for Basic Research (in part) [14-04-01244, AV] URL: (<http://www.rfbr.ru/rffi/ru>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** The authors have declared that no competing interests exist.

## Abstract

New polyanionic modifications of polyamide nucleic acid mimics were obtained. Thymine decamers were synthesized from respective chiral  $\alpha$ - and  $\gamma$ -monomers, and their enantiomeric purity was assessed. Here, we present the decamer synthesis, purification and characterization by MALDI-TOF mass spectrometry and an investigation of the hybridization properties of the decamers. We show that the modified  $\gamma$ -S-carboxyethyl-T<sub>10</sub> PNA forms a stable triplex with polyadenine DNA.

## Introduction

Among the various agents that are capable of antigen- and antisense action [1], artificial biopolymers, particularly peptide nucleic acids (PNAs) [2], occupy a special place. A structural unit of PNAs is the *N*-(2-aminoethyl)-glycine (*aeg*) fragment with a nucleic heterocyclic base attached via the acetyl linker. This structure, on the one hand, allows an effective recognition of complementary sequences by nucleic bases [3] due to “restrained flexibility” [4] and, on the other hand, makes *aeg*-PNAs resistant to protease- and nuclease-mediated degradation due to non-natural bonds [5].

The properties of *aeg*-PNAs are well studied. Upon interaction with ss- nucleic acid (NA) targets (deoxyribooligonucleotides (ODNs) or ribooligonucleotides), they form very stable anti-parallel and parallel duplexes [3], and the melting temperatures of the antiparallel duplexes are 10 to 15°C higher than those of the parallel duplexes. High sequence selectivity has been demonstrated for *aeg*-PNAs bases [3, 6], and this selectivity is markedly higher than that found for natural oligonucleotides and their analogues. The formation of triplexes between dsDNA and *aeg*-PNAs has been described [6–7]. Homopyrimidine *aeg*-PNAs are capable of insertion into dsDNA with ssDNA displacement [7]. Additionally, *aeg*-PNAs are capable of forming G-quadruplexes [8].

PNAs have already been investigated for more than 20 years, and a large number of modifications that increase PNA selectivity and affinity for nucleic acid targets or facilitate intracellular PNA delivery have been described [9–11].

A number of studies have shown that the  $\alpha$ -*R*- configuration [12–14],  $\beta$ -*S*- [15] and  $\gamma$ -*S*- configurations [16–23] of the acyclic backbone are beneficial for binding; in the latter case, accessible chiral agents, namely *L*-amino acids, were used as the starting compounds. A recent paper [24] describes promising amino- PNA derivatives (aminomethyl  $\alpha$ - and  $\gamma$ -PNAs), that exhibited high target affinity and selectivity. The best results were obtained for  $\gamma$ -*S*-derivatives, whereas  $\alpha$ -*R*-derivatives were significantly less efficient, and  $\alpha$ -*S*-derivatives had the lowest efficiency. High target affinity has also been reported for oligomers comprising monomers with substituents at both  $\alpha$ - and  $\gamma$ - positions with coordinated configurations of the chiral centres ( $\alpha$ -*R*-,  $\gamma$ -*S*) [25]. A number of studies have focused on chiral PNAs with guanidine moieties in the side chains [26]. Good cell membrane permeability has been demonstrated for such PNA derivatives, and the binding efficiency of the  $\gamma$ -*S*-derivatives [22, 27–28] was superior to that of the  $\alpha$ -*R*-derivatives [28]. All of the above-mentioned studies on PNA modification have aimed at developing new PNA-based molecular tools for fundamental genome studies and broadening the sphere of the practical applications of PNAs [29].

To solve the problems of self-aggregation and poor solubility, two scientific groups have independently proposed phosphono-PNAs [30–32]. ODN binding affinity and selectivity of phosphono-PNAs was inferior to that of *aeg*-PNAs. However, alternation of phosphono- and *aeg*- monomer units in a PNA oligomer resulted in improved binding efficiency [33]. Further improvements were achieved by the alternation of phosphono monomers and cyclic chiral 1*R*, 4*RS*-hydroxyproline-based monomers [34]. Thus, the incorporation of “stereochemically correct” units generally improved the hybridizing properties of such PNAs. Unlike *aeg*-PNA-synthesis, the synthesis of phosphono-PNAs is more similar to that of oligonucleotides than to that of peptides [35]. The preparation of mixed oligomers with *aeg*-units is therefore rather complex [36].

For various phosphono-PNAs derivatives, efficient delivery into cells upon complexation with lipofectamine has been demonstrated [37]. The same delivery principle has been described for *aeg*-PNAs derivatives with negatively charged peptide tails [38]. It has been shown that oligo-*L*-Asp-based fragments conjugated with *aeg*-PNAs are prone to complexation with lipofectamine, and the resulting complexes were readily transported into cells [39]. A longer the polyasparagine tail is associated with a higher the intracellular delivery efficiency.

A number of studies have focused on the incorporation of chiral monomers based on dicarboxylic amino acids into *aeg*-PNA oligomers. Nielsen et al. [13] showed that the introduction of thymine  $\alpha$ -monomers based on *D*-glutamic and *L*-asparaginic acids into the H-GT<sub>x</sub>AGAT<sub>x</sub>CACT<sub>x</sub>-NH<sub>2</sub> *aeg*-PNA decamer decreased the melting temperatures ( $T_m$ ) of complexes with native oligonucleotides compared with those of the unmodified PNA/DNA duplex. It has been found that the negatively charged modified decamers demonstrated increased sensitivity to non-complementary nucleosides (mismatches) in the DNA strand ( $\Delta T_m^{\text{perfect duplex-mismatch duplex}} = 20^\circ\text{C}$ ).

In a recent study conducted by Heemstra et al. [40],  $\gamma$ -*S*-carboxymethyl thymine monomers based on *L*-Asp were incorporated into Nielsen’s H-GT<sub>x</sub>AGAT<sub>x</sub>CACT<sub>x</sub>-NH<sub>2</sub> *aeg*-PNA decamer [13]. The resulting negatively charged PNA oligomers formed rather stable complexes with NA targets (particularly RNA) at moderate and high salt concentrations. Additionally, *aeg*-PNA with  $\gamma$ -*S*-carboxymethyl thymine monomers exhibited high sensitivity to mismatches in both DNA and RNA complements [41].

In recent years, some novel types of negatively charged PNAs have been reported, the and their charges are represented by *N*-alkyl-carboxyl groups in the achiral backbone [42] and

sulfomethyl groups at the  $\gamma$ -positions [43].  $\gamma$ -S-Sulfomethyl PNAs formed PNA<sub>2</sub>DNA triplexes and demonstrated good lipofectamine-mediated penetration into SKBR3 cells in model experiments.

It should be noted that all of the previous papers [13, 40, 42–43] describe PNA oligomers with negatively charged thymine monomers exclusively (with at most 3 residues in a chain). To summarize, the incorporation of negative charges into PNA oligomers is required to ensure PNA solubility and compatibility with standard cationic lipofection systems, whereas for an effective recognition of complementary NA sequences the configuration and the positions of chiral centres in the backbone are important. It has been shown earlier that more chiral monomers with the  $\gamma$ -S configuration is associated with a the higher NA binding efficiency [16, 23, 27]. However, no previous studies have investigated  $\gamma$ -chiral polyanionic NA mimics with a  $\gamma$ -S-chiral centre and a negative charge in each structural unit of the oligomer.

In the present work, we outline a synthesis of homothymine polyanionic PNAs based on *L*-Glu with chiral centres in the  $\gamma$ -S configuration (1, 2) and an investigation of their hybridization properties with complementary oligodeoxyriboadenylate d(A)<sub>10</sub>. Additionally, this work presents the first synthesis of a homothymine polyanionic PNA  $\alpha$ -oligomer (3).


## Results and Discussion

### Synthesis of monomers and estimation of their enantiomeric purity

The synthesis of the starting monomers 4 and 5 (Fig 1C) was performed using previously described methods [44–45], in which the key pseudopeptide intermediate was obtained *via* Mitsunobu condensation [46]. In a recent work, we reported the synthesis of monomer 4 *via* thymine alkylation with a bromoacetoamide precursor [47]. An alternative route for the preparation of monomer 5, in which the pseudopeptide intermediate is obtained by reductive *N*-alkylation, was outlined previously [13]. The syntheses of some other  $\gamma$ -PNA monomers based on dicarboxylic acids and meant for Fmoc-protocol oligomerization (*L*-Asp [40] and *L*-Glu [48]) have also been reported. The preparation of a different type of negatively charged  $\gamma$ -PNA monomers, namely the  $\gamma$ -sulfomethyl PNA monomers, was described previously [43] (the corresponding hydroxymethyl derivatives served as monomer precursors).

Because the stereochemical structure of chiral monomers in PNA oligomers impacts PNA binding with nucleic acid targets [9], we performed enantiomeric purity tests for the starting monomers 4 and 5 using direct and indirect chromatographic methods. The direct approaches for assessing the enantiomeric purity of chiral PNA monomers have been described in the literature [48–49]. Known indirect approaches include preliminary derivatization of *R*- and *S*-PNAs monomers at the *C*-termini with subsequent HPLC-analysis of the resulting diastereomeric mixtures [12–13] and derivatization of  $\gamma$ -chiral monomers at the *N*-termini with Mosher reagents [23–24, 27] with subsequent analysis of the diastereomeric mixtures by <sup>19</sup>F-NMR spectroscopy. The latter indirect approach was recently used for determining the enantiomeric purity of  $\alpha$ - monomers [24], and the purity was shown to be sufficient for subsequent oligomerization. Thus, according to the literature,  $\alpha$ - and  $\gamma$ - monomers do not racemize upon *N*-terminal derivatization.

The direct approach used in the present work involves the synthesis of two enantiomers (in our case, one from *L*-Glu ( $\gamma$ -S-4a) and one from *D*-Glu ( $\gamma$ -R-4b) [44]), the selection of the optimal conditions for their separation on a column with a chiral sorbent and the estimation of the enantiomeric purity in a selected system. For HPLC separation of the 4a/4b mixture, a hybrid sorbent (silica gel with immobilized eremomycin) was chosen. This chiral selector has been reported to possess good enantio-selectivity toward modified  $\alpha$ - and  $\beta$ -amino acids and their derivatives [50–51]. The separation of the *S*- and *R*-monomers, 4a and 4b, was relatively



**Fig 1. Schematic representation of PNA and DNA fragments.** (A) DNA fragment; (B) *aeg*-,  $\gamma$ - and  $\alpha$ -*ce*-PNAs; (C) Starting thymine monomers **4** and **5** and their conformers, which coexist in solution due to the reduced rotation along the N<sup>tert</sup>-C(O)-bond.


doi:10.1371/journal.pone.0140468.g001

efficient under the selected conditions (Fig 2A). The target ( $\gamma$ -S-) thymine monomer **4a** was analysed in this system (Fig 2B), and its enantiomeric purity was estimated to be > 99%. The same method was employed to assess the enantiomeric purity of the  $\alpha$ -S-monomer, **5b** (Fig 2C and 2D). The results of the direct method are shown in Fig 2B and 2D. Peak area calculations indicated that the enantiomeric purity of **5b** was > 99%.

According to the results of the direct tests, both the  $\alpha$ - and  $\gamma$ - monomers have sufficient enantiomeric purity and can be used for solid-phase oligomerization without further purification. The significant broadening and asymmetry of the HPLC peaks observed upon separation of the enantiomer mixtures **4a/4b** and **5a/5b** may be due to the existence of each enantiomer in solution as two constrained conformers (Fig 1C). To reliably exclude the presence of substantial enantiomeric impurities, we performed additional indirect tests with monomers **4** and **5**. For these tests, C-terminal diastereomers were obtained.

The enantiomers **4a/4b** and **5a/5b** were derivatized with the asymmetric reagent, *L*-IleOMe **6** (S1 Scheme) in the presence of *N*-ethyl-*N'*-(3-dimethylaminopropyl) carbodiimide (EDC) and 3-hydroxy-1,2,3-benzotriazine-4-on (DHbtOH) to yield the respective diastereomers **7a/7b** and **8a/8b** (Fig 3). The diastereomer structures were confirmed by <sup>1</sup>H-, and <sup>13</sup>C-NMR and elemental analysis. Elution systems for reverse-phase HPLC separation of the diastereomer pairs **7a/7b** and **8a/8b** (Fig 3A and 3C, respectively) were selected.


The enantiomeric purities of the target diastereomers **7a** and **8a** (Fig 3B and 3D, respectively) were estimated under the selected conditions. Importantly, no significant peak broadening was observed. Although we were unable to find a system for the complete separation of the diastereomers **7a** and **7b**, the system with heptane/isopropanol (88:12) provided the best separation. The enantiomeric purity of the target SS-diastereomer **7a** in this system was approximately 98%. The HPLC analysis of **8a** revealed that the portions of the SS- and RS-diastereomers were approximately 90.1 and 9.9%, respectively, which agrees with the results of previous studies [13].



**Fig 2. Chromatographic profiles of the PNA monomers (enantiomers).** (A) Mixture of **4a** and **4b** (*S*- and *R*- enantiomers of the  $\gamma$ -monomer); (B) *S*- enantiomer of the  $\gamma$ -monomer, **4a** (Conditions: Diasphere column 110-Chirasil-E-PA, 7  $\mu$ m; elution system: MeOH/CH<sub>3</sub>COOH = 96/4 (v/v); flow rate: 1 mL/min; UV-detection at 254 nm; temperature: 20°C); (C) Mixture of **5a** and **5b** (*R*- and *S*-enantiomers of the  $\alpha$ -monomer); (D) *S*-enantiomer of the  $\alpha$ -monomer, **5a** (Conditions: Diasphere column 110-Chirasil-E-PA, 7  $\mu$ m; elution system: MeOH/CH<sub>3</sub>COOH/TEA = 100/0.1/0.1 (v/v/v); flow rate: 0.5 mL/min; UV-detection at 254 nm; temperature: 20°C); R = CH<sub>2</sub>CH<sub>2</sub>COOBn.

doi:10.1371/journal.pone.0140468.g002

The results of the indirect enantiomeric purity test correlate well with those of the direct test only in the case of the  $\gamma$ -monomer (**4**), but certain racemization may have occurred upon *C*-terminal derivatization of the  $\alpha$ -monomer (**5**) to prevent good correlation between the two tests. It can be concluded that the direct tests are more accurate and adequate. It is known that  $\alpha$ -PNA monomers have a tendency to racemize upon activation of the *C*-terminal carboxyl group [52]. In this respect, these monomers are not good substrates for oligomerization. In the case of  $\gamma$ -monomers, on the contrary, racemization has never been observed under standard PNA synthesis conditions [53]. Thus, according to our data and the data reported by other groups,  $\gamma$ -monomers do not exhibit a tendency to racemize in indirect tests upon derivatization at both the *N*- and *C*-termini and are stereochemically more stable than  $\alpha$ -derivatives. The reproducibility of the results of direct and indirect tests for the  $\gamma$ -monomer **4** confirms this conclusion.



**Fig 3. Chromatographic profiles of the PNA monomer derivatives (diastereomers).** (A) Mixture of diastereomers **7a** and **7b**; (B) Diastereomer **7a** (Conditions: Luna column, 5  $\mu$ m, CN 100A, elution system: heptane/isopropanol (88/12), flow rate: 1 mL/min); (C) Mixture of diastereomers **8a** and **8b**; (D) Diastereomer **8a** (Conditions: Separon SGX RP-S C18 column, 5  $\mu$ m, 4x150 mm, elution system: acetonitrile/water (1/1), flow rate: 1 mL/min); R =  $-\text{CH}_2\text{CH}_2\text{COOBn}$ .

doi:10.1371/journal.pone.0140468.g003

## Solid-phase oligosynthesis

Monomer **4** was used for the synthesis of oligomers **1** and **2**. Monomer **5** was used for the synthesis of oligomer **3**. Solid-phase oligomerization was performed using a modified version of a previously published Boc-protocol for the preparation of *aeg*-PNAs [53]. The resin load of 0.1–0.2 mmol  $\text{NH}_2$ /g, the condensation reagent (HBTU), the Boc-cleavage mixture (TFA with 5% *m*-cresol) and the mixture used for oligomer cleavage from the polymer support were in accordance with the classical protocol. The modifications of the protocol were as follows: capping of the amino groups was performed by treatment with  $\text{Ac}_2\text{O}$  instead of Rapoport's reagent; [54] 3 (instead of 5) equivalents of the monomer were used at each condensation step; the resin was washed with DMF/DCM instead of Py; and the coupling time was extended from 10–15 minutes to 2 hours.

The thymine oligomer **1** was synthesized on a MBHA-resin using the manual device for solid-phase peptide synthesis (S2 Scheme). Final deblocking and cleavage of decamer **1** from the polymeric support were performed by the standard «low-high» TFOH method, [55] which includes treating the loaded resin with solutions of various trifluoromethanesulfonic acid (TFOH) contents for 1 hour at 0°C (the «low» solution (A): TFA-*m*-cresol:DMS:TFOH, 11:2:6:1, v/v/v/v; the «high» solution (B): TFOH:TFA:*m*-cresol, 1:8:1, v/v/v). The yield of decamer **1** was 0.7%. The yield of decamer **2** was too low under such conditions; therefore, we introduced several changes into the standard protocol. A glycine spacer between the resin and the

growing PNA chain was used in the case of decamer **2**. The deblocking and cleavage of decamer **2** from the support were performed by a previously described method [47]: the resin was pre-cooled to  $-30^{\circ}\text{C}$  and then treated with a mixture containing triisopropylsilane (TIS)—TFA:TfOH:TIS (3:1:0.1, v/v/v)—for 1 h at  $0^{\circ}\text{C}$ . Decamer **2** was obtained at a yield of 5.4%.

The  $\alpha$ -decamer (**3**) was obtained as a reference oligomer. Different methods were employed for its deblocking and cleavage. Resin treatment with “low” and “high” TfOH solutions for 1 h at  $0^{\circ}\text{C}$  resulted in complete degradation of the target oligomer according to MALDI-MS data. Decreasing the deblocking and cleavage times from 1 hour to 15 and 20 minutes, respectively, allowed us to obtain decamer **3** at a yield of 0.2%, but incomplete cleavage from the support under such conditions is very likely. Resin treatment with a mixture containing triethylsilane (TES)—TFA:TfOH:TES (3:1:0.1, v/v/v)—[56] lead to an insignificant increase in the yield of decamer **3** (0.9%). The maximum yield (2.3%) was obtained upon cleavage with the TFA:TfOH:TIS mixture (3:1:0.1, v/v/v, 1 hr,  $0^{\circ}\text{C}$ ) [47].

Oligomers **1**, **2** and **3** were purified by reverse-phase HPLC, and their structures were confirmed by MALDI-MS (S1, S2 and S3 Figs).

Because the starting  $\gamma$ -monomer **4** is stereochemically more stable, its oligomerization results in optically pure products, whereas in the case of the  $\alpha$ -monomer (**5**) partial racemization during the solid-phase synthesis is possible. To overcome this general problem of  $\alpha$ -PNA derivatives, a sub-monomeric approach has been proposed [57–58]; in this approach, carboxymethylated derivatives of the heterocycles are condensed with the pseudopeptide derivative immobilized on the solid phase. Unfortunately, this approach is inapplicable in the case of *L*-Glu-based monomers **4** and **5**. (Monomolecular cyclization of the pseudopeptides would primarily occur instead of the acylation of the secondary amino groups in the respective pseudopeptides with the carboxymethylated heterocycles [59]).


In the early studies on the preparation of  $\alpha$ -oligomers, which preceded the emergence of the sub-monomeric approach, the enantiomeric purity of the original monomers ( $\alpha$ -*S*- and  $\alpha$ -*R*) was  $\sim 90\%$  according to the results of *C*-terminal derivatization tests [13]. Despite the relatively low purity of the monomers, those studies convincingly demonstrated that the configuration of the chiral centres determines the hybridization properties of  $\alpha$ -oligomers to a significant extent.

Thus,  $\gamma$ -derivatives are preferable to  $\alpha$ -analogues in terms of the solid-phase synthesis efficiency and the stereochemical stability of the oligomers.

## Hybridization of homothymine $\gamma$ -PNAs with a homoadenine DNA strand

The hybridization properties of  $\gamma$ - and  $\alpha$ -thymine PNA decamers (**1** and **3**) were studied by physicochemical methods. Natural oligonucleotides that were complementary ( $\text{dA}_{10}$ ) and iso-sequential ( $\text{T}_{10}$ ) to  $\alpha$ - and  $\gamma$ -PNAs were obtained. Their synthesis, purification and MALDI-MS analysis were performed as described previously [60]. The thermal difference spectra (TDS) from the subtraction of the  $15^{\circ}\text{C}$  spectrum from the  $90^{\circ}\text{C}$  spectrum, CD spectra and UV-melting profiles of the PNA/DNA complexes (Fig 4) were compared with those of the iso-sequential DNA duplex ( $\text{dT}_{10}/\text{dA}_{10}$ ). The TDS data (Fig 4A) suggested that  $\gamma$ -PNA (**1**) may form either a duplex with increased stability (high TDS amplitude at 260 nm) or a triplex with  $\text{dA}_{10}$ , but the  $\alpha$ -PNA (**3**)/ $\text{dA}_{10}$  complex, if present, was relatively unstable. The TDS curve shapes of both  $\gamma$ -PNA (**1**)/ $\text{dA}_{10}$  and  $\alpha$ -PNA (**3**)/ $\text{dA}_{10}$  were rather similar to that of the DNA duplex. However the slight bathochromic shift indicates the presence of  $\text{PNA}_2\text{dA}_{10}$  triplexes [61].

The UV-melting data (Fig 4B) also indicate the formation of an extremely stable  $\gamma$ -PNA/ $\text{dA}_{10}$  complex ( $T_m^{\gamma\text{-PNA}/\text{dA}_{10}} > 80^{\circ}\text{C}$ ;  $T_m^{\text{dT}_{10}/\text{dA}_{10}} = 25 \pm 1^{\circ}\text{C}$ ) [62]. The melting profile of




**Fig 4. UV-melting and CD spectra of PNA/DNA and DNA/DNA complexes.** (A) Thermal difference spectra of the complexes; (B) Thermal denaturation profiles of the complexes; (C) CD spectra of the single-stranded oligonucleotides and PNAs. The molar ellipticity was calculated per 1 nucleotide. (D) CD spectra of the complexes. Conditions: 10 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.4), 140 mM KCl, 5 mM MgCl<sub>2</sub>. The concentration of each PNA or oligonucleotide was 2.5  $\mu$ M. The CD spectra were measured at 15°C.

doi:10.1371/journal.pone.0140468.g004

$\alpha$ -PNA/dA<sub>10</sub> bears no resemblance to a sigma curve, which may be due to the presence of high-order PNA/DNA structures, their non-cooperative melting or PNA self-aggregation. Decreasing the PNA/DNA or salt concentration up to 5 fold did not change the shape of the  $\alpha$ -PNA/dA<sub>10</sub> melting profile; therefore, it is unlikely that the complex is extremely stable. The CD spectra of the single-stranded PNAs (Fig 4C) are relatively similar to that of dT<sub>10</sub> in the 244–300 nm wavelength range with the exception of having a decreased amplitude and presenting a hypochromic shift of a negative band. CD spectra of the PNA/dA<sub>10</sub> complexes (Fig 4C) are substantially different from that of dT<sub>10</sub>/dA<sub>10</sub>, suggesting large differences in geometry or stoichiometry. We prepared a J-plot to clarify the stoichiometry of the  $\gamma$ -*ce*-H-(T<sub>10</sub>)-Gly-NH<sub>2</sub> (2)/dA<sub>10</sub> complex, as shown in Fig 5A, 5B and 5C. According to the J-Plot results, the PNA:DNA ratio in this extremely stable complex is in the range of 65:35 to 70:30. Therefore, the complex appears to be a PNA:DNA:PNA triplex. This finding agrees with the shape of the CD spectrum of ( $\gamma$ -PNA)<sub>2</sub>dA<sub>10</sub> (Fig 5D) because the negative band at approximately 210 nm is characteristic of triple helices [63].

The formation of the ( $\gamma$ -PNA)<sub>2</sub>dA<sub>10</sub> triplex agrees with the data presented in the literature. Analogous PNA<sub>2</sub>DNA triplexes have been reported for homopyrimidine *aeg*-PNA [6] and homothymine chimeric phosphono-PNAs/*aeg*-PNAs [33]. In a recent paper on homopyrimidine decamers containing *aeg*-monomers and thymine monomers with a sulfomethyl substituent at the  $\gamma$ -position, similar triplexes has also been described [43]. The relative orientation of





**Fig 5. J-Plots and CD spectra of  $\gamma$ -ce-H-(T<sub>10</sub>)-Gly-NH<sub>2</sub> (2)/dA<sub>10</sub>.** (A) Absorbance of the  $\gamma$ -ce-H-(T<sub>10</sub>)-Gly-OH (2)/dA<sub>10</sub> mixtures with various PNA/DNA ratios at 260 nm; (B) Absorbance of the mixtures at 275 nm; (C) Molar ellipticity at 263 nm. Conditions: 10 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.4), 140 mM KCl, 5 mM MgCl<sub>2</sub>. The summed PNA and DNA concentration was 7  $\mu$ M at each ratio; (D) CD spectra of the triplex. The molar ellipticity is given per 1 nucleotide in a strand. Conditions: 10 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 5 or 7.4), 140 mM KCl, 5 mM MgCl<sub>2</sub>. The triplex concentration was 1.8  $\mu$ M.

doi:10.1371/journal.pone.0140468.g005

the PNA strands in such complexes has not been unambiguously demonstrated. In DNA homopyrimidine<sub>2</sub>homopurine triplexes [64], the homopyrimidine strands are antiparallel. We hypothesize that this also is likely the case with our ( $\gamma$ -PNA)<sub>2</sub>dA<sub>10</sub> triplex, considering its remarkable stability. (A higher stability is characteristic of PNA<sub>2</sub>DNA triplexes that have the Watson–Crick PNA strand in the antiparallel orientation and the Hoogsteen strand in the parallel orientation to the DNA strand [65]).

The sequence-specificity of triplex formation, which is the key aspect in the context of antigen action, was studied. The sensitivity of our  $\gamma$ -PNA decamer to mismatches in a target ODN (S4 Fig) appears to be at least comparable with the sensitivities of homothymine aeg-PNA [6] and homothymine chimeric phosphono-PNA [33], although we were unable to estimate the sensitivity of  $\gamma$ -PNA accurately because of the extreme stability of the ( $\gamma$ -PNA)<sub>2</sub>dA<sub>10</sub> triplex (even at relatively low ionic strength its T<sub>m</sub> was > 80°C).

The stability of our ( $\gamma$ -ce-T<sub>10</sub>-PNAs)<sub>2</sub>d(A<sub>10</sub>) triplex is close to that described for aeg-PNAs [6], which suggests that carboxymethyl groups in a fully charged  $\gamma$ -oligomer do not hamper binding with an ODN target. At the same time, these negatively charged groups ensure PNA compatibility with the conditions required for targeting genomic DNA in culture and potentially *in vivo* (i.e., for PNA-mediated genome editing [66–68] or for gene expression regulation [69–70]). While unmodified aeg-PNAs bind DNA most efficiently at low salt concentrations [71], the new polyanionic PNAs work well at both moderate and low ionic strength.

## Conclusions

This study demonstrates the first synthesis of three *L*-Glu-based polyanionic nucleic acid mimics. The steric structures of the new PNA oligomers were predetermined using chiral  $\alpha$ - and  $\gamma$ -

monomers. The synthesis and purification of the polyanionic PNAs as well as their physico-chemical characteristics (particularly, their hybridization affinities toward complementary DNA) were described for  $\alpha$ - and  $\gamma$ -thymine decamers.

The results of the hybridization studies suggest that  $\alpha$ -*ce*-T<sub>10</sub>-PNAs are not prone to forming stable complexes with DNA and that  $\gamma$ -*ce*-T<sub>10</sub>-PNAs can form triplexes with high thermodynamic stability, similarly to classical *aeg*-PNAs [6]. Our findings indicate the advantages of  $\gamma$ -*ce*-PNAs over  $\alpha$ -*ce*-PNAs with respect to complexation with DNA, efficiency of solid-phase synthesis and stereochemical purity of the oligomers. Importantly, our results also suggest that the preorganization of the PNA backbone, which is dependent on the positions and configurations of the chiral centres, may be more significant for molecular recognition than the presence of charged side residues.

In conclusion, it should be noted that further studies of the negatively charged PNAs would require optimization of the solid-phase synthetic protocols. For a more detailed analysis of such compounds, mixed-sequence polyanionic PNAs (i.e., containing different heterocyclic bases) need to be obtained.

## Materials and Methods

The following reagents were used: *L*-H-IleOMe, EDC•HCl, TFA, DMS, TfOH, (Aldrich, USA); HBTU, MBHA-resin (polystyrene resin (4-methylbenzhydryl) amino containing 1% divinylbenzene; 0.5–0.7 mmol/g), acetic anhydride, glacial acetic acid, *m*-cresol, (Acros, USA); DIEA, pyridine (Lancaster, UK); water (Sigma LC-MS, USA); acetonitrile (for spectroscopy, Merck, Germany); DMF, ethanol, methanol, methylene chloride, diethyl ether, ethyl acetate, isopropanol, heptane, P<sub>2</sub>O<sub>5</sub>, EDTA, potassium hydrosulphate, sodium hydrocarbonate, sodium sulphate, ammonium acetate, chloroform-d<sub>1</sub>, sodium chloride, potassium chloride, MgCl<sub>2</sub>•6H<sub>2</sub>O, NaH<sub>2</sub>PO<sub>4</sub>•2H<sub>2</sub>O and Na<sub>2</sub>HPO<sub>4</sub>•12H<sub>2</sub>O.

The following solvents were purified before use: dichloromethane for solid-phase synthesis (washed twice with saturated NaHCO<sub>3</sub> and twice with water, dried over CaCl<sub>2</sub> and distilled over P<sub>2</sub>O<sub>5</sub>), ethanol (refluxed with magnesium shavings in the presence of iodine crystals and then distilled), DMF for solid-phase synthesis (maintained over 4-Å molecular sieves for 7 days and distilled over phthalic anhydride *in vacuo*), DIEA (distilled once over ninhydrin and then over KOH), diethyl ether (distilled twice over KOH and, immediately before the reaction, over LiAlH<sub>4</sub>), pyridine (distilled once over ninhydrin and then over KOH), acetonitrile (refluxed over P<sub>2</sub>O<sub>5</sub> for 2 h and then distilled over P<sub>2</sub>O<sub>5</sub>), triethylamine (distilled over KOH), acetic anhydride (distilled *in vacuo*), trifluoroacetic acid (distilled under atmospheric pressure), trifluoromethanesulfonic (distilled *in vacuo*), *m*-cresol (distilled *in vacuo*), and phenol (distilled *in vacuo*).

Natural oligonucleotides that were complementary (5'-(dA)<sub>10</sub>-3' and analogues with mismatches) and isosequential (5'-(dT)<sub>10</sub>-3') to  $\alpha$ - and  $\gamma$ -PNAs were synthesized, purified and characterized using MALDI-TOF MS, as described previously [60]. Prior to solid-phase PNA synthesis, the MBHA-resin was prepared as follows: resin was soaked in methylene chloride for 30 minutes and washed with methylene chloride (20 mL/g resin) in a funnel until a clear line of separation appeared. The solvent was then filtered, and the resin was dried under vacuum (oil pump vacuum) and washed on the filter with 5% DIEA in DCM (2x20 mL/g resin) and DCM (2x20 mL/g resin). The solvent was filtered, the resin was dried under vacuum and the number of amino groups on the resin was determined using the quantitative Kaiser test (0.62 mmol-NH<sub>2</sub>/g) [72].

Column chromatography was performed using Merck silica gel 60 (0.040–0.063 mm) with eluents as described below. Thin-layer chromatography (TLC) was performed using Merck

silica gel plates 60 F<sub>254</sub>. The TLC spots were visualized under UV light (254 nm), stained with 0.5% ninhydrin solution in ethanol or with a solution of Ce(SO<sub>4</sub>)<sub>2</sub> and phosphomolybdic acid in 10% aqueous H<sub>2</sub>SO<sub>4</sub> and heated. The solvents were removed via rotary evaporation under reduced pressure (15 mmHg). The compounds were dried *in vacuo* (2 mmHg).

The NMR spectra were obtained using a Bruker DPX-300 spectrometer. The chemical shifts are given in parts per million (ppm) relative to the signal of the internal standard (tetramethylsilane). The coupling constants are reported in Hertz. The abbreviations used for describing signal multiplicity in the <sup>1</sup>H-NMR-spectra are the following: s—singlet, d—doublet, dd—double doublet, t—triplet, q—quartet, m—multiplet.

### HPLC conditions for separating enantiomers and diastereomers

The HPLC data were analysed using MicroCal (TM) Origin Version 6.0 (Serial Number G73S4-9478-7000000).

### HPLC analysis and purification of decamers 1, 2 and 3

Analytical HPLC of the PNA oligomers **1**, **2** and **3** (see A, B and C, respectively) was performed as follows: (A) A Nucleosil C18 (4.6×250 mm; 5 μm) column was used in an Agilent 1100 chromatography system. Buffer A: 0.1 M AcNH<sub>4</sub> in water; buffer B: 0.1 M AcNH<sub>4</sub> in 50% acetonitrile; the gradient of buffer B was 2–12% (linear) over 30 min at a flow rate of 0.85 mL/min, and the eluent was monitored at 260 nm. Temperature: 45°C. (B) A Nucleosil C18 (4.6×250 mm; 5 μm) column was used in an Agilent 1100 chromatography system. Buffer A: 0.1 M AcNH<sub>4</sub> in water; buffer B: 0.1 M AcNH<sub>4</sub> in 50% acetonitrile; the gradient of buffer B was 5–14% (linear) over 25 min at a flow rate of 0.85 mL/min, and the eluent was monitored at 260 nm. Temperature: 45°C. (C) A Nucleosil C18 (4.6×250 mm, 5 μm) column was used in an Agilent 1100 chromatography system. Buffer A: 0.1 M AcNH<sub>4</sub> in water. Buffer B: 0.1 M AcNH<sub>4</sub> in 50% acetonitrile. The gradient of buffer B was 4–20% (linear) over 25 min at a flow rate of 0.85 mL/min, and the eluent was monitored at 260 nm. Temperature: 45°C.

The molecular weight of each oligomer was determined through MALDI-TOF MS analysis. The spectra were recorded using a MALDI-TOF MicroFlex mass spectrometer (Bruker, Germany) in the reflectron mode with the detection of positive ions and an acceleration voltage of +20 kV. For all mass spectrometry experiments, recrystallised α-cyano-4-hydroxycinnamic acid (Fluka, USA) was used as the MALDI matrix at a concentration of 25 mM in 50% water/acetonitrile and 0.1% TFA. The matrix and sample were mixed at a 1:1 (v/v) ratio prior to spotting. A total volume of 0.6 μL of the analyte/matrix mixture was deposited for each spot and air dried. A summary spectrum from 200 laser shots was accumulated for every PNA oligomer with the laser intensity was maintained slightly above the ionization threshold.

### Benzyl ester of (S) 4-((1S, 2R)-1-(methoxycarbonyl)-2-methylbutylcarbamoyl)-4-(2-(N-tert-butyloxycarbonyl)aminoethyl (thymine-1-acetyl))butyric acid (7a)

Monomer **4a** 97 mg (0.178 mmol) was dissolved in 10 mL of DMF, and 44 mg (0.231 mmol) of EDC-HCl was added. After 30 min, 32 mg (0.178 mmol) of HCl-L-Ile-OMe (**6**), 31 mg (0.231 mmol) of DhbtOH and 0.1 mL (0.445 mmol) of TEA were added to the reaction mixture. The mixture was stirred overnight, and then the solvent was evaporated under vacuum. Brine (10 mL) and ethyl acetate were added to the dry residue, and the mixture was extracted with ethyl acetate (2×10 mL). Combined organic fractions were washed with 3 mL of 0.1 M KHSO<sub>4</sub>, NaHCO<sub>3</sub> (1×5 mL) and brine (1×5 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The

residue was dried under high vacuum. TLC and column chromatography were performed in ethyl acetate. Compound **7a** was obtained at 45% yield (54 mg).  $R_f$ : 0.46;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  = 9.09, 9.04 (1H, 2s,  $-\text{NHThy}$ ); 7.55–7.28 (5H, m, -Ph); 7.24–7.17, 7.12–7.07 (1H, 2d,  $J$  = 7.8 and 8.1 Hz,  $-\text{C} = \text{O-NH(Ile)}$ ); 7.00, 6.90 (1H, 2s,  $\text{C}^6\text{HThy}$ ); 5.80–5.73, 5.72–5.65 (1H, 2t,  $J$  = 6.0 and 4.1 Hz,  $\text{BocNH-}$ ); 5.15, 5.11 (2H, 2s,  $-\text{COOCH}_2\text{Ph}$ ); 5.08–4.63 (2H, m;  $-\text{C} = \text{O-CH}_2\text{-Thy}$ ); 4.52–4.33 (2H, m;  $2\alpha\text{CH-}$ ); 3.77, 3.71 (3H, 2s,  $-\text{OCH}_3$ ); 3.67–3.54 (1H, m,  $-\text{CH(Ile)}$ ); 3.42–3.08 (4H, m,  $\text{BocNHCH}_2\text{CH}_2$ ); 2.54–2.12 (4H, m,  $-(\gamma, \beta)\text{CH}_2\text{Glu}$ ); 1.92, 1.89 (3H, 2s,  $-\text{CH}_3\text{Thy}$ ); 1.43 (9H, s,  $^t\text{Bu-}$ ); 1.29–1.22 (2H, q,  $J$  = 3.5 Hz,  $-\text{CH}_2\text{CH}_3\text{Ile}$ ); 0.98–0.84 (6H, m,  $-\text{2CH}_3(\text{Ile})$ ).  $^{13}\text{C-NMR}$  (only for one rotamer) ( $\text{CDCl}_3$ ):  $\delta$  = 172.9, 172.6, 170.9, 169.4, 164.4, 156.4, 151.1, 141.6, 135.7, 128.6, 128.4, 128.3, 110.5, 110.1, 79.8, 56.9, 52.2, 48.8, 43.7, 39.2, 36.9, 29.7, 28.4, 25.0, 24.3, 15.8, 12.3, 11.6; Anal. Calcd for  $\text{C}_{33}\text{H}_{47}\text{N}_5\text{O}_{10}$ : C, 58.83; H, 7.03; N, 10.39. Found: C, 58.88; H, 7.00; N, 9.88.

### Benzyl ester of (*R*) 4-((1*S*, 2*R*)-1-(methoxycarbonyl)-2-methylbutylcarbamoyl)-4-(2-(*N*-*tert*-butyloxycarbonyl)aminoethyl (thymine-1-acetyl))butyric acid (**7b**)

Compound **7b** was obtained analogously to **7a** from 102 mg (0.187 mmol) of **4b**, 46 mg (0.243 mmol) of EDC·HCl, 32 mg (0.178 mmol) of HCl·*L*-Ile-OMe (**6**), 33 mg (0.243 mmol) of DhbtOH and 0.1 mL (0.468 mmol) of TEA. TLC and column chromatography were performed in ethyl acetate. Yield 63 mg (50%).  $R_f$ : 0.46;  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  = 8.94, 8.89 (1H, 2s,  $-\text{NHThy}$ ); 7.44–7.28 (5H, m, -Ph); 7.24–7.18, 7.16–7.09 (1H, 2d,  $J$  = 8.2 and 7.1 Hz,  $-\text{C} = \text{O-NH(Ile)}$ ); 6.99, 6.90 (1H, 2s,  $\text{C}^6\text{HThy}$ ); 5.80–5.73, 5.72–5.64 (1H, 2t,  $J$  = 5.5 Hz,  $\text{BocNH-}$ ); 5.15, 5.11 (2H, 2s,  $-\text{COOCH}_2\text{Ph}$ ); 5.08–5.02, 4.95–4.90, 4.88–4.81, 4.78–4.69 (2H, 4d,  $J$  = 14.6, 8.5, 8.4 and 16.8 Hz,  $-\text{C} = \text{O-CH}_2\text{-Thy}$ ); 4.50–4.33 (2H, m,  $2\alpha\text{CH-}$ ); 3.77, 3.70 (3H, 2s,  $-\text{OCH}_3$ ); 3.66–3.53 (1H, m,  $-\text{CH(Ile)}$ ); 3.48–3.05 (4H, m,  $\text{BocNHCH}_2\text{CH}_2$ ); 2.63–2.50 (1H, m,  $-\text{CH(Ile)}$ ); 2.49–2.02 (4H, m,  $-(\gamma, \beta)\text{CH}_2\text{Glu}$ ); 1.89, 1.88 (3H, 2s,  $-\text{CH}_3\text{Thy}$ ); 1.43 (9H, s,  $^t\text{Bu-}$ ); 1.29–1.22 (2H, q,  $J$  = 3.4 Hz,  $-\text{CH}_2\text{CH}_3\text{Ile}$ ); 0.94–0.84 (6H, m,  $-\text{2CH}_3(\text{Ile})$ ).  $^{13}\text{C-NMR}$  (only for one rotamer) ( $\text{CDCl}_3$ ):  $\delta$  = 173.0, 172.5, 170.9, 169.4, 164.4, 156.4, 151.1, 141.1, 135.7, 128.6, 128.4, 128.3, 110.5, 79.8, 66.6, 56.9, 52.2, 48.8, 43.7, 39.2, 36.9, 29.3, 28.9, 25.0, 24.3, 15.8, 12.3, 11.6.

### Benzyl ester of (*S*) 4-(*N*-*tert*-butyloxycarbonyl)amino-5-(carbamoyl-*N*-(1*S*, 2*R*)-1-(methoxycarbonyl)-2-methylbutyl-*N*-(thymine-1-acetyl) amino) pentanoic acid (**8a**)

Compound **8a** was obtained analogously to **7a** from 100 mg (0.183 mmol) of **5a**, 53 mg (0.277 mmol) of EDC·HCl, 33 mg (0.181 mmol) of HCl·*L*-Ile-OMe (**6**), 37 mg (0.274 mmol) of DhbtOH and 0.1 mL (0.458 mmol) of TEA. TLC and column chromatography were performed in ethyl acetate.  $R_f$ : 0.55, yield: 40 mg (43%);  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  = 9.15 (1H, s,  $-\text{NHThy}$ ); 7.41–7.28 (5H, m, Ph); 7.04 (1H, s,  $\text{C}^6\text{HThy}$ ); 6.89–6.82 (1H, d,  $J$  = 6.0 Hz,  $-\text{C} = \text{O-NH(Ile)}$ ); 5.70–5.55 (1H, m,  $\text{BocNH-}$ ); 5.12, 5.10 (2H, 2s,  $-\text{COOCH}_2\text{Ph}$ ); 4.67–4.40 (2H, m,  $-\text{C} = \text{O-CH}_2\text{-Thy}$ ); 4.31–4.10 (2H, m,  $-\alpha\text{CH}_2\text{-(Gly)}$ ); 3.99–3.88 (1H, m,  $-\alpha\text{CH(Ile)}$ ); 3.85–3.79 (1H, m,  $\text{BocNHCHCH}_2$ ); 3.77, 3.68 (3H, 2s,  $-\text{OCH}_3$ ); 3.68–3.59 (1H, m,  $-\text{CH(Ile)}$ ); 3.54–3.38 (2H, m,  $\text{BocNHCHCH}_2$ ); 2.55–2.40 (2H, m,  $-(\gamma)\text{CH}_2\text{Glu}$ ); 1.89 (5H, m,  $-\text{CH}_3\text{Thy}$ ,  $-(\beta)\text{CH}_2\text{Glu}$ ); 1.41, 1.39 (9H, 2s,  $^t\text{Bu-}$ ); 1.22–1.10 (2H, m,  $-\text{CH}_2\text{CH}_3(\text{Ile})$ ); 0.99–0.84 (6H, m,  $-\text{2CH}_3(\text{Ile})$ ).  $^{13}\text{C-NMR}$  (only for one rotamer) ( $\text{CDCl}_3$ ):  $\delta$  = 173.2, 172.8, 172.4, 168.5, 164.3, 156.0, 151.1, 141.3, 135.8, 128.6, 128.2, 110.6, 79.9, 66.5, 56.7, 52.3, 51.4, 49.5, 48.0, 37.3, 30.8, 28.3, 27.5, 25.2, 15.5, 12.3, 11.5.

## Benzyl ester of (*R*) 4-(*N*-*tert*-butyloxycarbonyl)amino-5-(carbamoyl-*N*-(1*S*, 2*R*)-1-(methoxycarbonyl)-2-methylbutyl-*N*-(thymine-1-acetyl)amino) pentanoic acid (**8b**)

Compound **8b** was obtained analogously to **7a** from 76 mg (0.139 mmol) of **5b**, 35 mg (0.181 mmol) of EDC·HCl, 25 mg (0.139 mmol) of HCl·*L*-Ile-OMe (**6**), 24 mg (0.181 mmol) of DhbtOH and 0.1 mL (0.348 mmol) of TEA. TLC and column chromatography were performed in ethyl acetate.  $R_f$ : 0.55, yield: 86 mg (70%).  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  = 9.15 (1H, s, -NHThy); 7.42–7.28 (5H, m, Ph); 7.06 (1H, s,  $\text{C}^6\text{HThy}$ ); 6.86–6.79 (1H, d,  $J$  = 6.3 Hz, -C = O-NH(Ile)); 5.51–5.35 (1H, m, BocNH-); 5.12, 5.10 (2H, 2s, -COOCH<sub>2</sub>Ph); 4.61–4.45 (2H, m, -C = O-CH<sub>2</sub>-Thy); 4.28–4.15 (2H, m, - $\alpha\text{CH}_2$ (Gly)); 3.99–3.89 (1H, m, - $\alpha\text{CH}$ (Ile)); 3.88–3.78 (1H, m, BocNHCHCH<sub>2</sub>-); 3.76, 3.70 (3H, 2s, -OCH<sub>3</sub>); 3.66–3.55 (1H, m, -CH(Ile)); 3.53–3.37 (2H, m, BocNHCHCH<sub>2</sub>-); 2.54–2.51 (2H, m, -( $\gamma$ )CH<sub>2</sub>Glu); 1.89 (5H, m, -CH<sub>3</sub>Thy, -( $\beta$ )CH<sub>2</sub>Glu); 1.40, 1.39 (9H, 2s, <sup>t</sup>Bu-); 1.20–0.82 (8H, m, -CH<sub>2</sub>CH<sub>3</sub>(Ile), -2CH<sub>3</sub>(Ile)).  $^{13}\text{C-NMR}$  (only for one rotamer) ( $\text{CDCl}_3$ ):  $\delta$  = 173.1, 172.9, 172.3, 168.5, 164.3, 156.1, 151.1, 141.3, 135.8, 128.6, 128.2, 110.6, 79.9, 66.5, 56.6, 52.3, 51.2, 49.3, 48.0, 37.3, 30.8, 28.3, 27.5, 25.1, 15.5, 12.3, 11.5.

## Oligomer synthesis

**Manual solid-phase Boc-protocol synthesis (general procedure).** The negatively charged chiral PNA decamers were prepared on a MBHA resin (0.62 mmol/g) by the Boc-protocol from the C-terminus to N-terminus in the apparatus for manual solid-phase synthesis. All steps were performed at room temperature in a fluid bed. Agitation was performed using inert gas. The procedure included the following steps. 1) Washing the resin twice with DMF/DCM (1:1, v/v) for 2 min, and twice with DMF for 2 min. 2) Coupling with *in situ* neutralization: 0.085 M solution of HBTU (1 eq. per monomer) in DMF was added to a solution of PNA monomer (3 eq.) and DIEA (2 eq. per monomer) in DMF to obtain a final monomer concentration of 0.05 M. Pre-activation was performed for 5 min. The activated solution was transferred to the reactor, and coupling was allowed to proceed for 2 h. 3) Washing with DMF twice for 2 min and twice with DMF/DCM (1:1, v/v) for 2 min. 4) Monitoring coupling using Kaiser tests: if negative, continuing to the next step [72]. Otherwise, repeated coupling was performed under the same conditions. 5) Boc-deprotection with TFA/*m*-cresol (95:5, v/v), 1×10 min, 1×20 min. Steps 1–5 were repeated until the required sequence was obtained.

## Deprotection and cleavage of oligomers from resin

**Method A—«low-high» TfOH method (general procedure).** The oligomer-resin was dried *in vacuo* (0.1 mm Hg) and cooled on an ice bath for 5 min. Freshly prepared «low» TfOH solution (TFA:DMS:*m*-cresol:TfOH, 11:6:2:1) (10  $\mu\text{L}$  per 1 mg resin) was then added at 0°C, and the mixture was allowed to react at ambient temperature for 1 h for PNA deprotection. The solution was filtered, and the resin was washed with TFA (2×4 ml) on the filter. The oligomer was then cleaved from the solid support at 0°C for 1 h using freshly prepared «high» TfOH solution (TfOH:TFA:*m*-cresol, 1:8:1) (10  $\mu\text{L}$  per 1 mg resin). The filtrate was separated from the resin by filtration. The resin was washed with TFA (4×4 ml). The filtrate was evaporated and dried for 5 min *in vacuo* (0.1 mm Hg). The product was precipitated with anhydrous diethyl ether and then solubilised in water. The water phase was analysed through HPLC and mass spectrometry.

**Method B—mild «low-high» TfOH method.** The only difference from the general procedure (method A) is that the time of resin treatment with «low» and «high» TfOH solutions was

reduced (from 1 h to 15 min for the «low» solution and from 1 h to 20 min for the «high» solution).

**Method C—TES method.** The oligomer-resin was dried *in vacuo* (0.1 mm Hg). A TFA:TfOH:TES (3:1:0.1) solution (10  $\mu$ L per 1 mg resin) was then added and allowed to react at 0°C for 1 h. The filtrate was separated from the resin by filtration. The resin was washed with TFA (3 $\times$ 1 ml). The filtrate was evaporated and dried for 5 min *in vacuo* (0.1 mm Hg). The product was precipitated with anhydrous diethyl ether and then solubilised in water. The water phase was analysed through HPLC and mass spectrometry.

**Method D—TIS method.** The oligomer-resin was dried *in vacuo* (0.1 mm Hg) and cooled to -30°C. A TFA:TfOH:TIS (3:1:0.1) solution (10  $\mu$ L per 1 mg resin) was added and allowed to react at 0°C for 1 h. The filtrate was separated from the resin by filtration. The resin was washed with TFA (3 $\times$ 1 ml). The filtrate was evaporated and dried for 5 min *in vacuo* (0.1 mm Hg). The product was precipitated with anhydrous diethyl ether and then solubilised in water. The water phase was analysed through HPLC and mass spectrometry.

### H-[Thy-(L-Glu $\psi$ Gly)]<sub>10</sub>-NH<sub>2</sub> (1)

This negatively charged PNA decamer was assembled analogously to H-[Thy-(Gly $\psi$ L-Glu)]<sub>10</sub>-NH<sub>2</sub> (1). The synthesis was initiated on 150 mg of MBHA resin with a polymer loading of 0.20 mmol/g. All of the Kaiser tests were negative. The sample was purified by reverse-phase HPLC (B) and dried in a SpeedVac: white powder; MS (MALDI-TOF) *m/z*: 3400.0 (calcd. for C<sub>140</sub>H<sub>183</sub>N<sub>41</sub>O<sub>60</sub>: 3399.3). The decamer was cleaved from 57.9 mg of resin by method A. Yield: 257.0  $\mu$ g (0.7%).

### H-[Thy-(L-Glu $\psi$ Gly)]<sub>10</sub>-Gly (2)

This negatively charged PNA decamer was assembled analogously to H-[Thy-(L-Glu $\psi$ Gly)]<sub>10</sub>-NH<sub>2</sub> (2). The synthesis was initiated on 142 mg of MBHA resin with polymer loading of 0.20 mmol/g. The coupling reactions were monitored with Kaiser tests, all of which were negative with the exception of the T-1 and T-7 monomer coupling reactions (double coupling for 2 hr). The sample was purified by reverse-phase HPLC (C) and dried in a SpeedVac: white powder; MS (MALDI-TOF) *m/z*: 3457.0 (calcd. for C<sub>142</sub>H<sub>186</sub>N<sub>42</sub>O<sub>61</sub>: 3455.3). The decamer was cleaved from 38.4 mg of resin by method D. Yield: 1.24 mg (5.4%).

### H-[Thy-(Gly $\psi$ L-Glu)]<sub>10</sub>-NH<sub>2</sub> (3)

The protected negatively charged PNA decamer was assembled on MBHA resin (150 mg) with a polymer loading of 0.14 mmol/g (determined by quantitative ninhydrin reaction). The coupling reactions were monitored through Kaiser tests, all of which were negative (green-yellow colour with no coloration of the beads) with the exception of the T-2, T-4, T-7 and T-8 monomer coupling reactions (double coupling for 2 h). The sample was purified by reverse-phase HPLC (A) and dried in a SpeedVac: white powder; MS (MALDI-TOF) *m/z*: 3400.0 (calcd. for C<sub>140</sub>H<sub>183</sub>N<sub>41</sub>O<sub>60</sub>: 3399.3). The decamer was cleaved from 11 mg of resin by method A (complete degradation), from 9.0 mg of resin by method B with a yield of 7.8  $\mu$ g (0.2%); from 10.2 mg of resin by method C with a yield of 38.3  $\mu$ g (0.9%) and from 14.5 mg of resin by method D with a yield of 141.2  $\mu$ g (2.3%).

## Hybridization studies

The UV-spectra and thermal denaturation profiles of the PNA/DNA complexes and the DNA duplex were recorded with a Jasco UV 750 spectrophotometer (Japan) and a temperature

controlled cell in 5 mM sodium phosphate buffer, 140 mM KCl, 5 mM MgCl<sub>2</sub> (pH 7.46). The concentration of each oligonucleotide or PNA was 5 μM. The samples were denatured at 95°C for 5 min and slowly cooled to 20°C prior to analysis. The absorbance at 260 nm was measured as a function of temperature. The data were recorded every 0.5°C from 5 to 90°C. The melting temperature of the DNA duplex and the mismatched PNA<sub>2</sub>DNA triplexes were defined as the maxima of the first derivatives of absorption from temperature using MicroCal (TM) Origin Version 6.0 (Serial Number G73S4-9478-7000000). Circular dichroism (CD) spectra were obtained with a Jasco J-715 spectropolarimeter at 15°C. The samples were annealed in the same buffer and under the same conditions as used in thermal denaturation studies. The CD values ( $\Delta\epsilon$ ) are provided per mole of nucleotide.

## Supporting Information

**S1 Fig. Analytical HPLC profile (A) and MALDI-TOF spectrum (B) of PNA decamer 1.** (PDF)

**S2 Fig. Analytical HPLC profile (A) and MALDI-TOF spectrum (B) of PNA decamer 2.** (PDF)

**S3 Fig. Analytical HPLC profile (A) and MALDI-TOF spectrum (B) of PNA decamer 3.** (PDF)

**S4 Fig. Melting curves of  $\gamma$ -PNA<sub>2</sub>DNA triplexes (fully matched and mismatched).** (A) Buffer: 10 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.4), 140 mM KCl, 5 mM MgCl<sub>2</sub>. The concentration of each oligonucleotide or PNA was 2.5 μM. (B) Buffer: 10 mM Na<sub>2</sub>HPO<sub>4</sub> (pH 7.4), 10 mM KCl. The concentration of each oligonucleotide was 1 μM; PNA concentration was 2 μM. T<sub>m</sub> values were defined as the maxima of the first derivatives of absorption from temperature. (PDF)

**S1 Scheme. Synthesis of the PNA monomer derivatives (diastereomers).** (PDF)

**S2 Scheme. Synthesis of PNA oligomers.** (PDF)

## Author Contributions

Conceived and designed the experiments: YK GP. Performed the experiments: NB AD MT IP AV SE DE IS. Analyzed the data: YK GP. Contributed reagents/materials/analysis tools: YK GP AV. Wrote the paper: YK AV.

## References

1. Milligan JF, Matteucci MD, Martin JC. Current concepts in antisense drug design. *Journal of medicinal chemistry*. 1993; 36(14):1923–37. PMID: [8336333](#).
2. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. *Science*. 1991; 254(5037):1497–500. Epub 1991/12/06. PMID: [1962210](#).
3. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. *Nature*. 1993; 365(6446):566–8. Epub 1993/10/07. doi: [10.1038/365566a0](#) PMID: [7692304](#).
4. Hyrup B, Egholm M, Nielsen PE, Wittung P, Norden B, Buchardt O. Structure-Activity Studies of the Binding of Modified Peptide Nucleic Acids (PNAs) to DNA. *Journal of the American Chemical Society*. 1994; 116(18):7964–70. doi: [10.1021/ja00097a002](#)

5. Demidov VV, Potaman VN, Frank-Kamenetskii MD, Egholm M, Buchard O, Sonnichsen SH, et al. Stability of peptide nucleic acids in human serum and cellular extracts. *Biochemical pharmacology*. 1994; 48(6):1310–3. PMID: [7945427](#).
6. Egholm M, Nielsen PE, Buchardt O, Berg RH. Recognition of guanine and adenine in DNA by cytosine and thymine containing peptide nucleic acids (PNA). *Journal of the American Chemical Society*. 1992; 114(24):9677–8. doi: [10.1021/ja00050a068](#)
7. Cherny DY, Belotserkovskii BP, Frank-Kamenetskii MD, Egholm M, Buchardt O, Berg RH, et al. DNA unwinding upon strand-displacement binding of a thymine-substituted polyamide to double-stranded DNA. *Proceedings of the National Academy of Sciences of the United States of America*. 1993; 90(5):1667–70. Epub 1993/03/01. PMID: [8383322](#); PubMed Central PMCID: PMC45940.
8. Krishnan-Ghosh Y, Stephens E, Balasubramanian S. A PNA4Quadruplex. *Journal of the American Chemical Society*. 2004; 126(19):5944–5. doi: [10.1021/ja031508f](#) PMID: [15137741](#)
9. Corradini R, Sforza S, Tedeschi T, Totsingan F, Manicardi A, Marchelli R. Peptide nucleic acids with a structurally biased backbone. Updated review and emerging challenges. *Curr Top Med Chem*. 2011; 11(12):1535–54. Epub 2011/04/23. doi: BSP/CTMC/E-Pub/-000132-11-16 [pii]. PMID: [21510833](#).
10. Shiraishi T, Nielsen PE. Cellular Delivery of Peptide Nucleic Acids (PNAs). 2014; 1050:193–205. doi: [10.1007/978-1-62703-553-8\\_16](#)
11. Sugiyama T, Kittaka A. Chiral peptide nucleic acids with a substituent in the N-(2-aminoethyl)glycine backbone. *Molecules*. 2012; 18(1):287–310. Epub 2012/12/29. doi: molecules18010287 [pii] doi: [10.3390/molecules18010287](#) PMID: [23271467](#).
12. Dueholm KL, Petersen KH, Jensen DK, Egholm M, Nielsen PE, Buchardt O. Peptide nucleic acid (PNA) with a chiral backbone based on alanine. *Bioorganic & Medicinal Chemistry Letters*. 1994; 4(8):1077–80.
13. Nielsen PE, Haaime G, Lohse A, Buchardt O. Peptide Nucleic Acids (PNAs) Containing Thymine Monomers Derived from Chiral Amino Acids: Hybridization and Solubility Properties of D-Lysine PNA. *Angewandte Chemie International Edition in English*. 1996; 35(17):1939–42. doi: [10.1002/anie.199619391](#)
14. Sforza S, Corradini R, Ghirardi S, Dossena A, Marchelli R. DNA Binding of A D-Lysine-Based Chiral PNA: Direction Control and Mismatch Recognition. *European Journal of Organic Chemistry*. 2000; 2000(16):2905–13. doi: [10.1002/1099-0690\(200008\)2000:16<2905::aid-ejoc2905>3.0.co;2-d](#)
15. Sugiyama T, Imamura Y, Demizu Y, Kurihara M, Takano M, Kittaka A.  $\beta$ -PNA: Peptide nucleic acid (PNA) with a chiral center at the  $\beta$ -position of the PNA backbone. *Bioorganic & medicinal chemistry letters*. 2011; 21(24):7317–20. doi: [10.1016/j.bmcl.2011.10.017](#) PMID: [22050888](#)
16. Dragulescu-Andrasi A, Rapireddy S, Frezza BM, Gayathri C, Gil RR, Ly DH. A simple gamma-backbone modification preorganizes peptide nucleic acid into a helical structure. *J Am Chem Soc*. 2006; 128(31):10258–67. Epub 2006/08/03. doi: [10.1021/ja0625576](#) PMID: [16881656](#).
17. de Koning MC, Petersen L, Weterings JJ, Overhand M, van der Marel GA, Filippov DV. Synthesis of thiol-modified peptide nucleic acids designed for post-assembly conjugation reactions. *Tetrahedron*. 2006; 62(14):3248–58. doi: [http://dx.doi.org/10.1016/j.tet.2006.01.065](#)
18. Dose C, Seitz O. Convergent synthesis of peptide nucleic acids by native chemical ligation. *Org Lett*. 2005; 7(20):4365–8. Epub 2005/09/24. doi: [10.1021/ol051489+](#) PMID: [16178534](#).
19. Englund EA, Appella DH. Synthesis of gamma-substituted peptide nucleic acids: a new place to attach fluorophores without affecting DNA binding. *Org Lett*. 2005; 7(16):3465–7. Epub 2005/07/29. doi: [10.1021/ol051143z](#) PMID: [16048318](#).
20. Englund EA, Appella DH. Gamma-substituted peptide nucleic acids constructed from L-lysine are a versatile scaffold for multifunctional display. *Angew Chem Int Ed Engl*. 2007; 46(9):1414–8. Epub 2006/11/30. doi: [10.1002/anie.200603483](#) PMID: [17133633](#).
21. Tedeschi T, Sforza S, Corradini R, Marchelli R. Synthesis of new chiral PNAs bearing a dipeptide-mimic monomer with two lysine-derived stereogenic centres. *Tetrahedron Letters*. 2005; 46(48):8395–9. doi: [http://dx.doi.org/10.1016/j.tetlet.2005.09.157](#)
22. Jain DR, Anandi VL, Lahiri M, Ganesh KN. Influence of pendant chiral C(gamma)-(alkylideneamino/guanidino) cationic side-chains of PNA backbone on hybridization with complementary DNA/RNA and cell permeability. *J Org Chem*. 2014; 79(20):9567–77. Epub 2014/09/16. doi: [10.1021/jo501639m](#) PMID: [25221945](#).
23. Sahu B, Sacui I, Rapireddy S, Zanotti KJ, Bahal R, Armitage BA, et al. Synthesis and characterization of conformationally preorganized, (R)-diethylene glycol-containing gamma-peptide nucleic acids with superior hybridization properties and water solubility. *J Org Chem*. 2011; 76(14):5614–27. Epub 2011/05/31. doi: [10.1021/jo200482d](#) PMID: [21619025](#); PubMed Central PMCID: PMC3175361.



24. Mitra R, Ganesh KN. Aminomethylene peptide nucleic acid (am-PNA): synthesis, regio-/stereospecific DNA binding, and differential cell uptake of (alpha/gamma,R/S)am-PNA analogues. *J Org Chem*. 2012; 77(13):5696–704. Epub 2012/06/09. doi: [10.1021/jo300860f](https://doi.org/10.1021/jo300860f) PMID: [22676429](https://pubmed.ncbi.nlm.nih.gov/22676429/).
25. Sforza S, Tedeschi T, Corradini R, Marchelli R. Induction of Helical Handedness and DNA Binding Properties of Peptide Nucleic Acids (PNAs) with Two Stereogenic Centres. *European Journal of Organic Chemistry*. 2007; 2007(35):5879–85. doi: [10.1002/ejoc.200700644](https://doi.org/10.1002/ejoc.200700644)
26. Zhou P, Wang M, Du L, Fisher GW, Waggoner A, Ly DH. Novel Binding and Efficient Cellular Uptake of Guanidine-Based Peptide Nucleic Acids (GPNA). *Journal of the American Chemical Society*. 2003; 125(23):6878–9. doi: [10.1021/ja029665m](https://doi.org/10.1021/ja029665m) PMID: [12783535](https://pubmed.ncbi.nlm.nih.gov/12783535/)
27. Sahu B, Chenna V, Lathrop KL, Thomas SM, Zon G, Livak KJ, et al. Synthesis of conformationally pre-organized and cell-permeable guanidine-based gamma-peptide nucleic acids (gammaGPNAs). *J Org Chem*. 2009; 74(4):1509–16. Epub 2009/01/24. doi: [10.1021/jo802211n](https://doi.org/10.1021/jo802211n) [10.1021/jo802211n](https://doi.org/10.1021/jo802211n) [pii]. PMID: [19161276](https://pubmed.ncbi.nlm.nih.gov/19161276/); PubMed Central PMCID: [PMC2650244](https://pubmed.ncbi.nlm.nih.gov/PMC2650244/).
28. Zhou P, Dragulescu-Andrasi A, Bhattacharya B, O'Keefe H, Vatta P, Hyldig-Nielsen JJ, et al. Synthesis of cell-permeable peptide nucleic acids and characterization of their hybridization and uptake properties. *Bioorganic & medicinal chemistry letters*. 2006; 16(18):4931–5. Epub 2006/07/01. doi: [10.1016/j.bmcl.2006.06.052](https://doi.org/10.1016/j.bmcl.2006.06.052) PMID: [16809033](https://pubmed.ncbi.nlm.nih.gov/16809033/).
29. Nielsen PE. Peptide nucleic acids (PNA) in chemical biology and drug discovery. *Chem Biodivers*. 2010; 7(4):786–804. Epub 2010/04/17. doi: [10.1002/cbdv.201000005](https://doi.org/10.1002/cbdv.201000005) PMID: [20397216](https://pubmed.ncbi.nlm.nih.gov/20397216/).
30. Efimov VA, Choob MV, Buryakova AA, Chakhmakheva OG. Synthesis And Binding Study Of Phosphonate Analogues Of Pnas And Their Hybrids With Pnas. *Nucleosides and Nucleotides*. 1998; 17(9–11):1671–9. doi: [10.1080/07328319808004700](https://doi.org/10.1080/07328319808004700)
31. Uhlmann E, Will DW, Breipohl G, Langner D, Rytte A. Synthesis and Properties of PNA/DNA Chimeras. *Angewandte Chemie International Edition in English*. 1996; 35(22):2632–5. doi: [10.1002/anie.199626321](https://doi.org/10.1002/anie.199626321)
32. Doboszewski B, Groaz E, Herdewijn P. Synthesis of Phosphonoglycine Backbone Units for the Development of Phosphono Peptide Nucleic Acids. *European Journal of Organic Chemistry*. 2013; 2013(22):4804–15. doi: [10.1002/ejoc.201300523](https://doi.org/10.1002/ejoc.201300523)
33. Peyman A, Uhlmann E, Wagner K, Augustin S, Weiser C, Will DW, et al. PHONA–PNA Co-Oligomers: Nucleic Acid Mimetics with Interesting Properties. *Angewandte Chemie International Edition in English*. 1997; 36(24):2809–12. doi: [10.1002/anie.199728091](https://doi.org/10.1002/anie.199728091)
34. Efimov VA, Klykov VN, Chakhmakheva OG. Phosphono peptide nucleic acids with a constrained hydroxyproline-based backbone. *Nucleosides, nucleotides & nucleic acids*. 2003; 22(5–8):593–9. doi: [10.1081/NCN-120021962](https://doi.org/10.1081/NCN-120021962) PMID: [14565235](https://pubmed.ncbi.nlm.nih.gov/14565235/).
35. Efimov VA, Choob MV, Buryakova AA, Kalinkina AL, Chakhmakheva OG. Synthesis and evaluation of some properties of chimeric oligomers containing PNA and phosphono-PNA residues. *Nucleic acids research*. 1998; 26(2):566–75. doi: [10.1093/nar/26.2.566](https://doi.org/10.1093/nar/26.2.566) PMID: [9421517](https://pubmed.ncbi.nlm.nih.gov/9421517/)
36. Uhlmann E, Peyman A, Breipohl G, Will DW. PNA: Synthetic Polyamide Nucleic Acids with Unusual Binding Properties. *Angewandte Chemie International Edition*. 1998; 37(20):2796–823. doi: [10.1002/\(sici\)1521-3773\(19981102\)37:20<2796::aid-anie2796>3.0.co;2-k](https://doi.org/10.1002/(sici)1521-3773(19981102)37:20<2796::aid-anie2796>3.0.co;2-k)
37. Efimov VA, Birikh KR, Staroverov DB, Lukyanov SA, Tereshina MB, Zaraisky AG, et al. Hydroxyproline-based DNA mimics provide an efficient gene silencing in vitro and in vivo. *Nucleic acids research*. 2006; 34(8):2247–57. doi: [10.1093/nar/gkl249](https://doi.org/10.1093/nar/gkl249) PMID: [16670431](https://pubmed.ncbi.nlm.nih.gov/16670431/); PubMed Central PMCID: [PMC1456331](https://pubmed.ncbi.nlm.nih.gov/PMC1456331/).
38. Shiraishi T, Hamzavi R, Nielsen PE. Subnanomolar antisense activity of phosphonate-peptide nucleic acid (PNA) conjugates delivered by cationic lipids to HeLa cells. *Nucleic acids research*. 2008; 36(13):4424–32. Epub 2008/07/04. doi: [gkn401](https://doi.org/10.1093/nar/gkn401) [pii] doi: [10.1093/nar/gkn401](https://doi.org/10.1093/nar/gkn401) PMID: [18596083](https://pubmed.ncbi.nlm.nih.gov/18596083/); PubMed Central PMCID: [PMC2490735](https://pubmed.ncbi.nlm.nih.gov/PMC2490735/).
39. Bae YM, Kim MH, Yu GS, Um BH, Park HK, Lee H-i, et al. Enhanced splicing correction effect by an oligo-aspartic acid–PNA conjugate and cationic carrier complexes. *Journal of Controlled Release*. 2014; 175:54–62. doi: [10.1016/j.jconrel.2013.12.015](https://doi.org/10.1016/j.jconrel.2013.12.015) PMID: [24369124](https://pubmed.ncbi.nlm.nih.gov/24369124/)
40. De Costa NT, Heemstra JM. Evaluating the effect of ionic strength on duplex stability for PNA having negatively or positively charged side chains. *PLoS ONE*. 2013; 8(3):e58670. Epub 2013/03/14. doi: [10.1371/journal.pone.0058670](https://doi.org/10.1371/journal.pone.0058670) PONE-D-12-40535 [pii]. PMID: [23484047](https://pubmed.ncbi.nlm.nih.gov/23484047/); PubMed Central PMCID: [PMC3590165](https://pubmed.ncbi.nlm.nih.gov/PMC3590165/).
41. De Costa NT, Heemstra JM. Differential DNA and RNA sequence discrimination by PNA having charged side chains. *Bioorganic & medicinal chemistry letters*. 2014; 24(10):2360–3. Epub 2014/04/16. doi: [10.1016/j.bmcl.2014.03.059](https://doi.org/10.1016/j.bmcl.2014.03.059) PMID: [24731279](https://pubmed.ncbi.nlm.nih.gov/24731279/).

42. De Cola C, Manicardi A, Corradini R, Izzo I, De Riccardis F. Carboxyalkyl peptoid PNAs: synthesis and hybridization properties. *Tetrahedron*. 2012; 68(2):499–506. doi: <http://dx.doi.org/10.1016/j.tet.2011.11.017>
43. Avitabile C, Moggio L, Malgieri G, Capasso D, Di Gaetano S, Saviano M, et al. gamma Sulphate PNA (PNA S): highly selective DNA binding molecule showing promising antigene activity. *PloS one*. 2012; 7(5):e35774. Epub 2012/05/16. doi: [10.1371/journal.pone.0035774](https://doi.org/10.1371/journal.pone.0035774) PONE-D-11-24563 [pii]. PMID: [22586450](https://pubmed.ncbi.nlm.nih.gov/22586450/); PubMed Central PMCID: PMC3346730.
44. Prokhorov DI, Kirillova YG, Boyarskaya NP, Tevashova AN, Esipova OV, Zvonkova EN, et al. Synthesis of Thymine-Containing Monomers of Negatively Charged Peptide Nucleic Acids. *Pharmaceutical Chemistry Journal*. 2005; 39(6):323–8. doi: [10.1007/s11094-005-0145-5](https://doi.org/10.1007/s11094-005-0145-5)
45. Boyarskaya NP, Kirillova YG, Stotland EA, Prokhorov DI, Zvonkova EN, Shvets VI. Synthesis of two new thymine-containing negatively charged PNA monomers. *Doklady Chemistry*. 2006; 408(1):57–60. doi: [10.1134/s0012500806050016](https://doi.org/10.1134/s0012500806050016)
46. Falkiewicz B, Kołodziejczyk AS, Liberek B, Wiśniewski K. Synthesis of achiral and chiral peptide nucleic acid (PNA) monomers using Mitsunobu reaction. *Tetrahedron*. 2001; 57(37):7909–17. doi: [10.1016/s0040-4020\(01\)00759-1](https://doi.org/10.1016/s0040-4020(01)00759-1)
47. Dezhnev AV, Tankevich MV, Nikolskaya ED, Smirnov IP, Pozmogova GE, Shvets VI, et al. Synthesis of anionic peptide nucleic acid oligomers including gamma-carboxyethyl thymine monomers. *Mendeleev Communications*. 2015; 25(1):47–8. doi: [10.1016/j.mencom.2015.01.017](https://doi.org/10.1016/j.mencom.2015.01.017)
48. Huang H, Joe G-H, Choi S-R, Kim S-N, Kim Y-T, Pak C-S, et al. Synthesis of Enantiopure gamma-Glutamic Acid Functionalized Peptide Nucleic Acid Monomers. *Bulletin of the Korean Chemical Society*. 2010; 31(7):2054–6. doi: [10.5012/bkcs.2010.31.7.2054](https://doi.org/10.5012/bkcs.2010.31.7.2054)
49. Huang H, Joe GH, Choi SR, Kim SN, Kim YT, Pak HS, et al. Preparation and determination of optical purity of gamma-lysine modified peptide nucleic acid analogues. *Archives of Pharmacal Research*. 2012; 35(3):517–22. doi: [10.1007/s12272-012-0315-4](https://doi.org/10.1007/s12272-012-0315-4) PMID: [22477199](https://pubmed.ncbi.nlm.nih.gov/22477199/)
50. Kuznetsov MA, Nesterenko PN, Vasiyarov GG, Staroverov SM. Sorbents with immobilized glycopeptide antibiotics for separating optical isomers by high-performance liquid chromatography. *Applied Biochemistry and Microbiology*. 2006; 42(6):536–44. doi: [10.1134/s0003683806060020](https://doi.org/10.1134/s0003683806060020)
51. Kuznetsov MA, Nesterenko PN, Vasiyarov GG, Staroverov SM. High-performance liquid chromatography of alpha-amino acid enantiomers on eremomycin-modified silica. *Journal of Analytical Chemistry*. 2011; 63(1):57–64. doi: [10.1134/s1061934808010115](https://doi.org/10.1134/s1061934808010115)
52. Corradini R, Di Silvestro G, Sforza S, Palla G, Dossena A, Nielsen PE, et al. Direct enantiomeric separation of N-aminoethylamino acids: determination of the enantiomeric excess of chiral peptide nucleic acids (PNAs) by GC. *Tetrahedron: Asymmetry*. 1999; 10(11):2063–6. doi: [10.1016/s0957-4166\(99\)00210-4](https://doi.org/10.1016/s0957-4166(99)00210-4)
53. Christensen L, Fitzpatrick R, Gildea B, Petersen KH, Hansen HF, Koch T, et al. Solid-Phase synthesis of peptide nucleic acids. *Journal of Peptide Science*. 1995; 1(3):175–83. doi: [10.1002/psc.310010304](https://doi.org/10.1002/psc.310010304) PMID: [9222994](https://pubmed.ncbi.nlm.nih.gov/9222994/)
54. Watkins BE, Rapoport H. Synthesis of benzyl and benzyloxycarbonyl base-blocked 2'-deoxyribonucleosides. *The Journal of Organic Chemistry*. 1982; 47(23):4471–7. doi: [10.1021/jo00144a014](https://doi.org/10.1021/jo00144a014)
55. Tam JP, Heath WF, Merrifield RB. Mechanisms for the removal of benzyl protecting groups in synthetic peptides by trifluoromethanesulfonic acid-trifluoroacetic acid-dimethyl sulfide. *Journal of the American Chemical Society*. 1986; 108(17):5242–51. doi: [10.1021/ja00277a031](https://doi.org/10.1021/ja00277a031)
56. Kirillova YG, Tankevich MV, Prokhorov DI, Shvets VI. Peculiarities of solid-phase synthesis of negatively charged chiral polyamides as nucleic acid mimics. *Russian Journal of Organic Chemistry*. 2014; 49(12):1768–76. doi: [10.1134/s1070428013120117](https://doi.org/10.1134/s1070428013120117)
57. Sforza S, Tedeschi T, Corradini R, Ciavardelli D, Dossena A, Marchelli R. Fast, Solid-Phase Synthesis of Chiral Peptide Nucleic Acids with a High Optical Purity by a Submonomeric Strategy. *European Journal of Organic Chemistry*. 2003; 2003(6):1056–63. doi: [10.1002/ejoc.200390148](https://doi.org/10.1002/ejoc.200390148)
58. Tedeschi T, Sforza S, Maffei F, Corradini R, Marchelli R. A Fmoc-based submonomeric strategy for the solid phase synthesis of optically pure chiral PNAs. *Tetrahedron Letters*. 2008; 49(33):4958–61. doi: [10.1016/j.tetlet.2008.05.114](https://doi.org/10.1016/j.tetlet.2008.05.114)
59. Boyarskaya NP, Prokhorov DI, Kirillova YG, Zvonkova EN, Shvets VI. Synthesis of protected pseudo-peptides from dicarboxylic amino acids by Mitsunobu condensation. *Tetrahedron Letters*. 2005; 46(43):7359–62. doi: [10.1016/j.tetlet.2005.08.121](https://doi.org/10.1016/j.tetlet.2005.08.121)
60. Pozmogova GE, Zaitseva MA, Smirnov IP, Shvachko AG, Murina MA, Sergeenko VI. Anticoagulant effects of thioanalogs of thrombin-binding DNA-aptamer and their stability in the plasma. *Bulletin of experimental biology and medicine*. 2010; 150(2):180–4. PMID: [21240367](https://pubmed.ncbi.nlm.nih.gov/21240367/).

61. Mergny JL. Thermal difference spectra: a specific signature for nucleic acid structures. *Nucleic acids research*. 2005; 33(16):e138–e. doi: [10.1093/nar/gni134](https://doi.org/10.1093/nar/gni134) PMID: [16157860](https://pubmed.ncbi.nlm.nih.gov/16157860/)
62. Vargas-Baca I, Mitra D, Zulyniak HJ, Banerjee J, Sleiman HF. Solid-Phase Synthesis of Transition Metal Linked, Branched Oligonucleotides. *Angewandte Chemie*. 2001; 113(24):4765–8. doi: [10.1002/1521-3757\(20011217\)113:24<4765::aid-ange4765>3.0.co;2-d](https://doi.org/10.1002/1521-3757(20011217)113:24<4765::aid-ange4765>3.0.co;2-d)
63. Manzini G, Xodo LE, Gasparotto D, Quadrifoglio F, van der Marel GA, van Boom JH. Triple helix formation by oligopurine-oligopyrimidine DNA fragments. Electrophoretic and thermodynamic behavior. *Journal of molecular biology*. 1990; 213(4):833–43. doi: [10.1016/S0022-2836\(05\)80267-0](https://doi.org/10.1016/S0022-2836(05)80267-0) PMID: [2359124](https://pubmed.ncbi.nlm.nih.gov/2359124/).
64. Frank-Kamenetskii MD, Mirkin SM. Triplex DNA structures. *Annu Rev Biochem*. 1995; 64:65–95. Epub 1995/01/01. doi: [10.1146/annurev.bi.64.070195.000433](https://doi.org/10.1146/annurev.bi.64.070195.000433) PMID: [7574496](https://pubmed.ncbi.nlm.nih.gov/7574496/).
65. Krupnik OL, Lazurkin Iu S. [PNA-DNA triplexes: stability and specificity]. *Genetika*. 2005; 41(7):869–83. Epub 2005/09/13. PMID: [16152791](https://pubmed.ncbi.nlm.nih.gov/16152791/).
66. Chin JY, Reza F, Glazer PM. Triplex-forming peptide nucleic acids induce heritable elevations in gamma-globin expression in hematopoietic progenitor cells. *Mol Ther*. 2013; 21(3):580–7. Epub 2013/01/23. doi: [mt2012262](https://doi.org/10.1038/mt.2012.262) [pii] doi: [10.1038/mt.2012.262](https://doi.org/10.1038/mt.2012.262) PMID: [23337982](https://pubmed.ncbi.nlm.nih.gov/23337982/); PubMed Central PMCID: PMC3589157.
67. Bahal R, Quijano E, McNeer NA, Liu Y, Bhunia DC, Lopez-Giraldez F, et al. Single-stranded gammaPNAs for in vivo site-specific genome editing via Watson-Crick recognition. *Curr Gene Ther*. 2014; 14(5):331–42. Epub 2014/09/02. doi: [CGT-Epub-61907](https://doi.org/10.1038/mt.2012.262) [pii]. PMID: [25174576](https://pubmed.ncbi.nlm.nih.gov/25174576/); PubMed Central PMCID: PMC4333085.
68. Nik-Ahd F, Bertoni C. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy. *Stem Cells*. 2014; 32(7):1817–30. Epub 2014/04/23. doi: [10.1002/stem.1668](https://doi.org/10.1002/stem.1668) PMID: [24753122](https://pubmed.ncbi.nlm.nih.gov/24753122/).
69. Wang G, Xu X, Pace B, Dean DA, Glazer PM, Chan P, et al. Peptide nucleic acid (PNA) binding-mediated induction of human gamma-globin gene expression. *Nucleic Acids Res*. 1999; 27(13):2806–13. Epub 1999/06/22. doi: [gkc425](https://doi.org/10.1093/nar/27.13.2806) [pii]. PMID: [10373600](https://pubmed.ncbi.nlm.nih.gov/10373600/); PubMed Central PMCID: PMC148492.
70. Kolevzon N, Nasereddin A, Naik S, Yavin E, Dzikowski R. Use of peptide nucleic acids to manipulate gene expression in the malaria parasite *Plasmodium falciparum*. *PLoS ONE*. 2014; 9(1):e86802. Epub 2014/01/28. doi: [10.1371/journal.pone.0086802](https://doi.org/10.1371/journal.pone.0086802) PONE-D-13-36470 [pii]. PMID: [24466246](https://pubmed.ncbi.nlm.nih.gov/24466246/); PubMed Central PMCID: PMC3899306.
71. Nielsen PE. Peptide nucleic acid: a versatile tool in genetic diagnostics and molecular biology. *Curr Opin Biotechnol*. 2001; 12(1):16–20. Epub 2001/02/13. doi: [S0958-1669\(00\)00170-1](https://doi.org/10.1016/S0958-1669(00)00170-1) [pii]. PMID: [11167067](https://pubmed.ncbi.nlm.nih.gov/11167067/).
72. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. *Analytical biochemistry*. 1970; 34(2):595–8. doi: [10.1016/0003-2697\(70\)90146-6](https://doi.org/10.1016/0003-2697(70)90146-6) PMID: [5443684](https://pubmed.ncbi.nlm.nih.gov/5443684/)